A recent study, published in JAMA Dermatology, investigated whether there was an association between insurance type and surgical delays for patients with melanoma.
A recent study, published in JAMA Dermatology, investigated whether there was an association between insurance type and surgical delays for patients with melanoma.
This population-based, retrospective cohort study was comprised of 7629 patients that received a diagnosis of melanoma between 2004 and 2011 in North Carolina. The results showed that Medicaid patients were significantly more likely to experience delays in surgery when compared with privately insured patients.
Data were collected from the North Carolina Cancer Registry and then linked to administrative claims from Medicare, Medicaid, and private insurance. The inclusion criteria were patients with a diagnosis of melanoma from stages 0-3, and continuous insurance enrollment from at least 1 month prior to the diagnosis, and at least 12 months after the diagnosis.
The results showed that of the 7629 patients included, 4210 (55%) female; mean age, 64 years. The breakdown of each insurance type was 48% (n = 3631) Medicare, 48% (n = 3667) privately insured, and 4% (n = 331) Medicaid patients. According to the study, privately insured patients were the least likely to experience a delay in definitive surgery, followed by Medicare and Medicaid patients (519 [14%], 609 [17%], and 79 [24%], respectively; P  <  .001). When researchers adjusted for demographic, the risk of surgical delay was significantly increased in patients with Medicaid when compared with private insurance (Risk Ratio [RR], 1.36; 95% CI, 1.09-1.70).
Findings showed that delays were more likely in nonwhite patients (RR, 1.38; 95% CI, 1.02-1.87). Surgical delays were less likely if the physician was performing the surgery (RR, 0.82; 95% CI, 0.72-0.93) or the diagnosing clinician was a dermatologist (RR, 0.81; 95% CI, 0.71-0.93) as compared with a non-dermatologist.
Timely administration of treatment for any disease is an important aspect of healthcare quality. Delays in treatment, defined by this study as surgery occurring more than 6 weeks after diagnosis, could be detrimental to the patient’s health. Researchers found that Medicaid patients experienced the most surgical delays. While treatment delays were common, they were less prevalent in patients diagnosed or surgically treated by a dermatologist. A reduction in delays in melanoma surgery could be achieved through better access to specialty care, as well as better cross-disciplinary coordination.
"Delays in melanoma care could be reduced through better access to specialty care and cross-disciplinary partnerships to ensure that patients can safely navigate the treatment episode," the authors concluded. "Understanding why Medicaid patients receive less timely care for melanoma should be given further scrutiny."
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More